MediWound Ltd. (NASDAQ:MDWD) Stock Has Consensus Target Price of $33.00 According to Brokerages

by · The Markets Daily

Shares of MediWound Ltd. (NASDAQ:MDWD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $33.00.

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 26th. Alliance Global Partners reaffirmed a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Finally, TD Cowen reiterated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th.

Read Our Latest Analysis on MediWound

MediWound Stock Performance

NASDAQ MDWD opened at $12.22 on Friday. The stock’s 50-day moving average price is $13.38 and its two-hundred day moving average price is $14.73. MediWound has a 1 year low of $12.19 and a 1 year high of $20.03.

MediWound (NASDAQ:MDWD – Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. As a group, equities analysts expect that MediWound will post -2.37 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.20% of the stock is owned by insiders.

Institutional Trading of MediWound

A hedge fund recently raised its position in MediWound stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of MediWound Ltd. (NASDAQ:MDWD – Free Report) by 8.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 200,005 shares of the biopharmaceutical company’s stock after buying an additional 16,081 shares during the period. MediWound makes up about 1.8% of Silverberg Bernstein Capital Management LLC’s holdings, making the stock its 16th biggest position. Silverberg Bernstein Capital Management LLC owned approximately 1.56% of MediWound worth $3,222,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

(Get Free Report)

MediWound Ltd. (NASDAQ: MDWD) is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company’s products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers.

Featured Stories